ReviewJournal of oncology2021
Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
Review in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.European radiology · 2025Pooled it
- From fragmented neurotechnologies to closed-loop brain health systems: integrating artificial intelligence, digital health, digital twins, and advanced materials for brain disorders.Frontiers in bioengineering and biotechnology · 2026Article
- Comparative evaluation of dynamic susceptibility contrast MRI techniques for brain imaging at 3T and 5T magnetic field strengths.Frontiers in human neuroscience · 2026Article
- AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.Frontiers in immunology · 2026Review
- Differentiating tumor recurrence and pseudoprogression in postoperative gliomas using pseudo-continuous arterial spin labeling (pCASL) technique.BMC medical imaging · 2025Article
- Dynamic Susceptibility Contrast Magnetic Resonance Imaging with Carbon-Encapsulated Iron Nanoparticles Navigated to Integrin Alfa V Beta 3 Receptors in Rat Glioma.Nanomaterials (Basel, Switzerland) · 2025Article
- Contrast-free dynamic susceptibility contrast using sinusoidal and bolus oxygenation challenges.NMR in biomedicine · 2024Article
- Cerebral Microvascular Perfusion Assessed in Elderly Adults by Spin-Echo Dynamic Susceptibility Contrast MRI at 7 Tesla.Tomography (Ann Arbor, Mich.) · 2024Article
- The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma.JCI insight · 2023Article
- Article
- Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives.Biomarker research · 2023Review
- Imaging in translational cancer research.Cancer biology & medicine · 2022Review
- Focused ultrasound for the treatment of glioblastoma.Journal of neuro-oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurately and quickly differentiating true progression from pseudoprogression in glioma patients is still a challenge. This study aims to explore if dynamic susceptibility contrast- (DSC-) MRI can improve the evaluation of glioma progression. We enrolled 65 glioma patients with suspected gadolinium-enhancing lesion. Longitudinal MRI follow-up (mean 590 days, range: 210-2670 days) or re-operation (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.